STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTIX
  4. [8-K] Protagenic Therapeutics, Inc.new Reports Material Event

Protagenic Therapeutics (PTIX) CFO Alexander Arrow set to exit role

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. reported a leadership change in its finance function. On March 31, 2026, the Board of Directors notified Chief Financial Officer Alexander Arrow, MD that his employment with the company will be terminated, effective April 30, 2026. This change affects the company’s senior management team but the filing does not describe any replacement plan or additional terms.

Positive

  • None.

Negative

  • Chief Financial Officer termination: On March 31, 2026, the Board notified CFO Alexander Arrow, MD that his employment will be terminated effective April 30, 2026, creating a near-term transition in the company’s financial leadership.

Insights

Protagenic’s CFO is scheduled to depart at the end of April 2026.

The company states that on March 31, 2026 its Board notified Chief Financial Officer Alexander Arrow, MD that his employment will be terminated effective April 30, 2026. This represents a change in leadership over financial reporting and capital planning.

Departures from the CFO role can raise questions about continuity in financial oversight and internal control processes, especially for smaller or emerging growth companies. The filing does not describe reasons for the termination or announce a successor, so future disclosures will be needed to understand the longer-term finance leadership structure.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Board notice date March 31, 2026 Date Board notified CFO of termination
CFO termination effective date April 30, 2026 Effective date for Chief Financial Officer’s employment termination
Company address ZIP code 10010 ZIP code for principal executive offices in New York, NY
Company phone number 212-994-8200 Telephone number for Protagenic Therapeutics, Inc.
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers;"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02. Departure of Directors or Certain Officers; Election of Directors;"
principal executive offices financial
"149 Fifth Avenue , Suite 500 , New York , NY | | 10010 (Address of principal executive offices)"
OTC Markets market
"Protagenic Therapeutics, Inc. Common Stock | | PTIX | | OTC Markets"
Over-the-counter (OTC) markets are trading venues where buyers and sellers deal directly through dealers or electronic networks instead of on a formal exchange; think of a neighborhood flea market versus a supermarket. They matter to investors because OTC-listed stocks often represent smaller or international companies with fewer reporting requirements, which can mean lower liquidity, wider price swings and higher risk but sometimes earlier access to growth opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What leadership change did Protagenic Therapeutics (PTIX) disclose in this 8-K?
Protagenic Therapeutics disclosed that its Chief Financial Officer, Alexander Arrow, MD, will have his employment terminated. The Board notified him on March 31, 2026, and the termination is effective April 30, 2026, altering the company’s senior finance leadership.

When is the Protagenic Therapeutics CFO termination effective?
The CFO termination is effective on April 30, 2026. The company’s Board notified Chief Financial Officer Alexander Arrow, MD on March 31, 2026, providing one month between notice and effective date for transition and handover of responsibilities.

Which Protagenic Therapeutics executive is affected by this 8-K filing?
The filing concerns Alexander Arrow, MD, the Chief Financial Officer of Protagenic Therapeutics. The Board informed him that his employment will be terminated effective April 30, 2026, signaling a change in the company’s top financial management role.

Does Protagenic Therapeutics state why the CFO is being terminated?
The company does not state a reason for the CFO’s termination in this disclosure. It only reports that the Board notified Chief Financial Officer Alexander Arrow, MD on March 31, 2026, that his employment will end effective April 30, 2026.

Is a successor CFO named in the Protagenic Therapeutics 8-K?
No successor CFO is named in this disclosure. The company only reports that Chief Financial Officer Alexander Arrow, MD was notified of termination effective April 30, 2026, without mentioning an interim or permanent replacement for the finance leadership role.
false 0001022899 0001022899 2026-03-31 2026-03-31 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockMember 2026-03-31 2026-03-31 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockWarrantsMember 2026-03-31 2026-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): March 31, 2026

 

PROTAGENIC THERAPEUTICS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   001-12555   06-1390025

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

149 Fifth Avenue, Suite 500, New York, NY   10010
(Address of principal executive offices)   (Zip Code)

 

212-994-8200

(Company’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Protagenic Therapeutics, Inc. Common Stock   PTIX   OTC Markets
Protagenic Therapeutics, Inc. Common Stock Warrants   PTIXW   OTC Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 31, 2026, the Board of Directors of Protagenic Therapeutics, Inc. (the “Company”) notified Alexander Arrow, MD, the Company’s Chief Financial Officer, that his employment with the Company will be terminated effective April 30, 2026.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTAGENIC THERAPEUTICS, INC.
     
Date: April 6, 2026 By: /s/ Garo H. Armen
  Name: Garo H. Armen
  Title: Executive Chairman

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents